KM estimates of OS from diagnosis by therapy group. Log-rank statistics were used to compare the 3 therapy groups. No significant difference was observed between the RHCVAD and RCHOP+HDT/ASCR (P = .98) or between the RCHOP+HDT/ASCR and RCHOP (P = .20) therapy groups. Patients in the RHCVAD therapy group had marginally greater OS than those in the RCHOP therapy group (P = .07). Data were not yet mature enough to examine survival for patients receiving RHCVAD+HDT/ASCR. Median follow-up: 33 months; 3-year OS: RCHOP+HDT/ASCR = 87% (95% CI: 64%, 95%), RHCVAD = 85% (95% CI: 74%, 92%), RCHOP = 69% (95% CI: 46%, 83%).